

Ref. No: 2722
Date: 29/07/26
Subject: Treatment with immunology medicines

REQUEST

I am conducting analysis on treatment with immunology medicines and kindly request your help.

I would be grateful if you could tell me how many patients were treated in the 3 months between April and June 2026 for the list of drugs named in the questions below.

Please fill in the template below with the number of patients or a format of your choice. Please include data for all hospitals in your organisation.

Q1. How many patients were treated in **total** regardless of diagnosis with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

Drug Name	<u>Total</u> number of patients treated <u>regardless of diagnosis</u>
Adalimumab	
Abrocitinib	
Apremilast	
Baricitinib	
Bimekizumab	
Brodalumab	
Certolizumab Pegol	
Deucravacitinib	
Dupilumab	
Etanercept	
Guselkumab	
Infliximab	
Ixekizumab	
Lebrikizumab	
Nemolizumab	
Risankizumab	
Secukinumab	

Tildrakizumab	
Tralokinumab	
Ustekinumab	

Q2. How many patients were treated by the **Dermatology** or **Rheumatology** Departments or Clinics with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

Drug Name	Number of patients treated by the <u>Dermatology Department</u>	Number of patients treated by the <u>Rheumatology Department</u>
Adalimumab		
Apremilast		
Baricitinib		
Bimekizumab		
Brodalumab		
Certolizumab Pegol		
Etanercept		
Guselkumab		
Infliximab		
Ixekizumab		
Risankizumab		
Secukinumab		
Ustekinumab		

Q3. How many patients with **Plaque Psoriasis** or **Psoriatic Arthritis** across all departments were treated with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

Drug Name	Number patients with <u>Plaque Psoriasis</u>	Number patients with <u>Psoriatic Arthritis</u>
Adalimumab		
Bimekizumab		
Secukinumab		
Apremilast		
Certolizumab Pegol		
Etanercept		
Guselkumab		
Infliximab		
Ixekizumab		
Risankizumab		
Ustekinumab		
Brodalumab		
Deucravacitinib		

Q4. How many patients with **Atopic Dermatitis** across all departments were treated with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

Drug Name	<u>Atopic Dermatitis</u>
Baricitinib	
Dupilumab	
Nemolizumab	

Q5. How many patients with **Hidradenitis Suppurativa** across all departments were treated with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

Drug Name	<u>Hidradenitis Suppurativa</u>
Adalimumab	
Bimekizumab	
Secukinumab	

RESPONSE

Q1. How many patients were treated in **total** regardless of diagnosis with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

Drug Name	<u>Total</u> number of patients treated <u>regardless of diagnosis</u>
Adalimumab	793
Abrocitinib	8
Apremilast	95
Baricitinib	82
Bimekizumab	12
Brodalumab	0
Certolizumab Pegol	44
Deucravacitinib	0
Dupilumab	147
Etanercept	269
Guselkumab	53
Infliximab	335
Ixekizumab	24

Lebrikizumab	6
Nemolizumab	<5
Risankizumab	62
Secukinumab	102
Tildrakizumab	<5
Tralokinumab	8
Ustekinumab	218

Q2. How many patients were treated by the **Dermatology** or **Rheumatology** Departments or Clinics with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

Drug Name	Number of patients treated by the <u>Dermatology Department</u>	Number of patients treated by the <u>Rheumatology Department</u>
Adalimumab	128	421
Apremilast	91	<5
Baricitinib	13	65
Bimekizumab	0	12
Brodalumab	0	0
Certolizumab Pegol	<5	38
Etanercept	<5	266
Guselkumab	31	11
Infliximab	<5	34
Ixekizumab	11	14
Risankizumab	7	<5
Secukinumab	16	86
Ustekinumab	34	17

Unable to answer Q 3,4,5 as we do not hold information about specific indications.